Reference #: #1663 Product: Drugs Recipient:

Recipient Name

Rich Mangini

RPK Pharmaceuticals Inc.

3281 Whipple Rd.
Union City, CA 94587
United States

Issuing Office: Center for Drug Evaluation and Research

United States

Mr. Rich Mangini,

The Food and Drug Administration has completed an evaluation of your firm’s corrective actions in response to our Warning Letter # 1663. Based on our evaluation, it appears that you have addressed the violations contained in this Warning Letter and corrected the data deficiencies. Future FDA regulatory activities will further assess the adequacy and sustainability of these corrections.

This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority. The Agency expects you and your firm to maintain compliance and to continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.

Sincerely,
/S/
Carolyn E. Becker, J.D.
Director, Office of Unapproved Drugs & Labeling Compliance
Center for Drug Evaluation and Research
Office of Compliance
U.S. Food and Drug Administration
Tel: 301-796-8801
[email protected]

CC: San Juan District Office